deferoxamine has been researched along with Hypogonadism in 18 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Hypogonadism: Condition resulting from deficient gonadal functions, such as GAMETOGENESIS and the production of GONADAL STEROID HORMONES. It is characterized by delay in GROWTH, germ cell maturation, and development of secondary sex characteristics. Hypogonadism can be due to a deficiency of GONADOTROPINS (hypogonadotropic hypogonadism) or due to primary gonadal failure (hypergonadotropic hypogonadism).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Deferiprone (L1) was found to have greater efficacy at depleting myocardial iron than desferrioxamine (DFX)." | 5.32 | Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major. ( Chang, JS; Peng, CT; Tsai, CH; Wu, KH, 2004) |
| " We compared the efficacy of oral deferiprone (L1) to subcutaneous desferrioxamine (DFO) chelation therapy for the prevention of major endocrinopathies (growth hormone insufficiency, diabetes mellitus and gonadal dysfunction) among patients with beta-thal major to see if we could offer these patients an easier and more painless way to reduce their body iron load and related endocrine complications." | 5.12 | Comparison of oral and subcutaneous iron chelation therapies in the prevention of major endocrinopathies in beta-thalassemia major patients. ( Peng, CT; Tsai, CH; Tsai, FJ; Wang, CH; Wu, KH, 2006) |
| "In this study, we compared the long-term effects of different iron chelation regimens (deferoxamine, deferiprone, deferoxamine + deferiprone, and deferasirox) in preventing or reversing endocrinopathy (diabetes mellitus, hypothyroidism, or hypogonadism) and bone disease (measured through DEXA) in 165 adults with β-thalassemia major (TM) (mean age 39." | 3.83 | Longitudinal changes of endocrine and bone disease in adults with β-thalassemia major receiving different iron chelators over 5 years. ( Daniele, C; Equitani, F; Guitarrini, MR; Losardo, A; Maffei, L; Monti, S; Pasin, M; Poggi, M; Pugliese, P; Smacchia, MP; Sorrentino, F; Terlizzi, F; Toscano, V, 2016) |
| "Delayed puberty was present in 18." | 2.72 | Impact of long-term iron chelation therapy on growth and endocrine functions in thalassaemia. ( De Sanctis, V; Fortini, M; Galati, MC; Gasser, T; Raiola, G; Roos, M, 2006) |
| "Hypogonadism was noted in 59% of the patients who reached pubertal age, and short stature was found in 36% of patients who reached final height." | 1.33 | Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patients. ( Carmi, D; Kornreich, L; Miskin, H; Phillip, M; Shalitin, S; Tamary, H; Weintrob, N; Yaniv, I; Zilber, R, 2005) |
| "Deferiprone (L1) was found to have greater efficacy at depleting myocardial iron than desferrioxamine (DFX)." | 1.32 | Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major. ( Chang, JS; Peng, CT; Tsai, CH; Wu, KH, 2004) |
| "Juvenile hemochromatosis is a rare genetic disorder that causes iron overload." | 1.31 | Juvenile hemochromatosis associated with B-thalassemia treated by phlebotomy and recombinant human erythropoietin. ( Brunello, F; Camaschella, C; De Gobbi, M; Mazza, U; Paccotti, P; Pasquero, P, 2000) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (27.78) | 18.7374 |
| 1990's | 2 (11.11) | 18.2507 |
| 2000's | 9 (50.00) | 29.6817 |
| 2010's | 2 (11.11) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Picardo, E | 1 |
| Mitidieri, M | 1 |
| Minniti, E | 1 |
| Ambroggio, S | 1 |
| D'Addato, F | 1 |
| Benedetto, C | 1 |
| Gregori, G | 1 |
| Baù, MG | 1 |
| Poggi, M | 1 |
| Sorrentino, F | 1 |
| Pugliese, P | 1 |
| Smacchia, MP | 1 |
| Daniele, C | 1 |
| Equitani, F | 1 |
| Terlizzi, F | 1 |
| Guitarrini, MR | 1 |
| Monti, S | 1 |
| Maffei, L | 1 |
| Losardo, A | 1 |
| Pasin, M | 1 |
| Toscano, V | 1 |
| De Sanctis, V | 4 |
| PESTEL, M | 1 |
| Wu, KH | 2 |
| Chang, JS | 1 |
| Tsai, CH | 2 |
| Peng, CT | 2 |
| Borgna-Pignatti, C | 1 |
| Rugolotto, S | 1 |
| De Stefano, P | 1 |
| Zhao, H | 1 |
| Cappellini, MD | 1 |
| Del Vecchio, GC | 1 |
| Romeo, MA | 1 |
| Forni, GL | 1 |
| Gamberini, MR | 1 |
| Ghilardi, R | 1 |
| Piga, A | 1 |
| Cnaan, A | 1 |
| Shalitin, S | 1 |
| Carmi, D | 1 |
| Weintrob, N | 1 |
| Phillip, M | 1 |
| Miskin, H | 1 |
| Kornreich, L | 1 |
| Zilber, R | 1 |
| Yaniv, I | 1 |
| Tamary, H | 1 |
| Vogiatzi, MG | 1 |
| Autio, KA | 1 |
| Mait, JE | 1 |
| Schneider, R | 1 |
| Lesser, M | 1 |
| Giardina, PJ | 1 |
| Roos, M | 1 |
| Gasser, T | 1 |
| Fortini, M | 1 |
| Raiola, G | 1 |
| Galati, MC | 1 |
| Wang, CH | 1 |
| Tsai, FJ | 1 |
| Kidson-Gerber, GL | 1 |
| Francis, S | 1 |
| Lindeman, R | 1 |
| Economidou, J | 1 |
| Tuschy, U | 1 |
| Schmidt, U | 1 |
| Meinhold, J | 1 |
| Wutke, K | 1 |
| Jensen, CE | 1 |
| Tuck, SM | 1 |
| Old, J | 1 |
| Morris, RW | 1 |
| Yardumian, A | 1 |
| Hoffbrand, AV | 1 |
| Wonke, B | 2 |
| De Gobbi, M | 1 |
| Pasquero, P | 1 |
| Brunello, F | 1 |
| Paccotti, P | 1 |
| Mazza, U | 1 |
| Camaschella, C | 1 |
| Simon, M | 1 |
| Bourel, M | 1 |
| Allegra, A | 1 |
| Capra, M | 1 |
| Cuccia, L | 1 |
| Pulejo, ML | 1 |
| Raineri, L | 1 |
| Corselli, F | 1 |
| Traina, MC | 1 |
| Giannola, C | 1 |
| La Grutta, A | 1 |
| Vullo, C | 1 |
| Katz, M | 1 |
| Hoffbrand, VA | 1 |
| Di Palma, A | 1 |
| Bagni, B | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Iron-mediated Vascular Disease in Sickle Cell Disease.[NCT01239901] | 150 participants (Actual) | Observational | 2009-12-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
4 reviews available for deferoxamine and Hypogonadism
| Article | Year |
|---|---|
The first case of breast cancer in thalassemic patient: case report and review of literature.
Topics: Adult; beta-Thalassemia; Blood Transfusion; Breast Neoplasms; Carcinoma, Intraductal, Noninfiltratin | 2015 |
Growth and puberty and its management in thalassaemia.
Topics: Adolescent; Adult; Amenorrhea; beta-Thalassemia; Body Height; Calcification, Physiologic; Child; Def | 2002 |
Problems related to treatment of beta-thalassaemia major.
Topics: Adolescent; Adult; Bone Diseases; Child; Child, Preschool; Deferoxamine; Encephalitis; Female; Hormo | 1982 |
[Idiopathic haemochromatosis. I. Clinical, biological and therapeutic aspects (author's transl)].
Topics: Bloodletting; Bone Diseases; Cardiomyopathies; Deferoxamine; Diabetes Mellitus; Female; Ferritins; H | 1979 |
2 trials available for deferoxamine and Hypogonadism
| Article | Year |
|---|---|
Impact of long-term iron chelation therapy on growth and endocrine functions in thalassaemia.
Topics: Adolescent; Adult; beta-Thalassemia; Body Height; Child; Child, Preschool; Deferoxamine; Female; Glu | 2006 |
Comparison of oral and subcutaneous iron chelation therapies in the prevention of major endocrinopathies in beta-thalassemia major patients.
Topics: Administration, Oral; Adolescent; Adult; beta-Thalassemia; Chelation Therapy; Child; Combined Modali | 2006 |
12 other studies available for deferoxamine and Hypogonadism
| Article | Year |
|---|---|
Longitudinal changes of endocrine and bone disease in adults with β-thalassemia major receiving different iron chelators over 5 years.
Topics: Adult; Benzoates; beta-Thalassemia; Chelation Therapy; Deferasirox; Deferiprone; Deferoxamine; Diabe | 2016 |
[HEMOCHROMATOSIS].
Topics: Alcoholism; Biopsy; Blood Chemical Analysis; Bloodletting; Chelating Agents; Deferoxamine; Diabetes | 1964 |
Combined therapy with deferiprone and desferrioxamine successfully regresses severe heart failure in patients with beta-thalassemia major.
Topics: Adult; beta-Thalassemia; Cardiovascular Agents; Deferiprone; Deferoxamine; Diabetes Complications; D | 2004 |
Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine.
Topics: Adult; Age Factors; Arrhythmias, Cardiac; Blood Transfusion; Chelation Therapy; Cohort Studies; Defe | 2004 |
Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patients.
Topics: Adolescent; Adult; beta-Thalassemia; Biomarkers; Body Height; Child; Child, Preschool; Deferoxamine; | 2005 |
Low bone mineral density in adolescents with beta-thalassemia.
Topics: Adolescent; Adult; Anthropometry; beta-Thalassemia; Blood Transfusion; Bone Density; Bone Diseases, | 2005 |
Management and clinical outcomes of transfusion-dependent thalassaemia major in an Australian tertiary referral clinic.
Topics: Adult; Age Factors; Australia; Cardiomyopathies; Deferiprone; Deferoxamine; Diabetes Mellitus; Drug | 2008 |
[Long-term study in congenital refractory anemia and secondary siderosis].
Topics: Adolescent; Anemia, Aplastic; Deferoxamine; Dwarfism; Female; Hemosiderosis; Humans; Hypogonadism; H | 1982 |
Incidence of endocrine complications and clinical disease severity related to genotype analysis and iron overload in patients with beta-thalassaemia.
Topics: Adolescent; Adult; beta-Thalassemia; Child; Deferoxamine; Endocrine System Diseases; Female; Genotyp | 1997 |
Juvenile hemochromatosis associated with B-thalassemia treated by phlebotomy and recombinant human erythropoietin.
Topics: Adrenal Cortex Hormones; Adrenal Insufficiency; Adult; Arrhythmias, Cardiac; beta-Thalassemia; Chela | 2000 |
Hypogonadism in beta-thalassemic adolescents: a characteristic pituitary-gonadal impairment. The ineffectiveness of long-term iron chelation therapy.
Topics: Adolescent; Chelation Therapy; Child; Deferoxamine; Dose-Response Relationship, Drug; Estradiol; Fem | 1990 |
Endocrine complications in thalassaemia major.
Topics: Adolescent; Adult; Blood Transfusion; Deferoxamine; Diabetes Mellitus, Type 1; Female; Humans; Hypog | 1989 |